peptides expert FAQ

No. AOD-9604 doesn't suppress endogenous GH production or desensitize ghrelin receptors. You can add it to an existing MK 677 or CJC1295 Ipamorelin protocol without a washout period. The two mechanisms are additive, not competitive. Continue your current GH secretagogue dose and layer AOD-9604 at standard research doses (300–500mcg twice daily) without adjustment.

Pair Dihexa with GLP-1 receptor agonists or metabolic peptides without concern. These operate through completely separate pathways. Administering Dihexa in the morning for acute cognitive demands and a GLP-1 analog like mazdutide before meals addresses two distinct systems without overlap. The only timing consideration is injection site rotation to avoid localised tissue saturation if both are administered subcutaneously.

Monitor clearance windows and consider spacing administration by 6–8 hours. CYP3A4 enzyme capacity is finite. Administering two peptides requiring the same metabolic pathway simultaneously extends half-life for both compounds unpredictably. If stacking is unavoidable, reduce doses proportionally (e.g., 0.5mg/kg Dihexa instead of 1mg/kg) to avoid hepatic congestion. Most researchers underestimate this constraint and attribute side effects to the peptides rather than the metabolic bottleneck.